RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,100 Shares

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $45.00, for a total value of $139,500.00. Following the completion of the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at $1,901,070. The trade was a 6.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Tuesday, November 26th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.88, for a total value of $142,228.00.
• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The stock was sold at an average price of $46.00, for a total value of $224,250.00.
• On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total value of $139,500.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The stock was sold at an average price of $46.13, for a total value of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total value of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.79, for a total value of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total value of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.68, for a total value of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total value of $154,318.00.

RxSight Stock Performance

Shares of RxSight stock opened at $46.06 on Wednesday. RxSight, Inc. has a twelve month low of $28.88 and a twelve month high of $66.54. The business has a 50-day moving average price of $49.20 and a 200 day moving average price of $52.57.

Analysts Set New Price Targets

RXST has been the subject of a number of recent research reports. Stifel Nicolaus reduced their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Wells Fargo & Company reduced their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Oppenheimer reduced their price objective on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Finally, Jefferies Financial Group initiated coverage on RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $61.63.

Hedge Funds Weigh In On RxSight

Hedge funds have recently made changes to their positions in the company. Arete Wealth Advisors LLC acquired a new position in RxSight in the 3rd quarter valued at $215,000. Geode Capital Management LLC raised its holdings in RxSight by 17.7% in the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock valued at $40,398,000 after acquiring an additional 122,775 shares during the last quarter. Barclays PLC raised its holdings in RxSight by 389.8% in the 3rd quarter. Barclays PLC now owns 58,786 shares of the company’s stock valued at $2,906,000 after acquiring an additional 46,783 shares during the last quarter. MML Investors Services LLC acquired a new stake in RxSight in the 3rd quarter valued at about $452,000. Finally, MCIA Inc raised its holdings in RxSight by 5.7% in the 3rd quarter. MCIA Inc now owns 8,459 shares of the company’s stock valued at $385,000 after acquiring an additional 459 shares during the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.